The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
An article from
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
Published June 26, 2026
Getty Images
European regulators are backing approval of Acadia Pharmaceuticals’ Daybue, following a re-examination of the data the drugmaker submitted after the agency initially voted against authorizing the medicine for a rare brain disorder.
EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
European Regulators Move to Revoke Avacopan Authorization
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
FDA reverses course on Regenxbio’s childhood gene therapy after rejection
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
FDA advisory panels are back, with new meetings for Replimune, Capricor
EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
Trial data 'can no longer be relied upon' to demonstrate drug's efficacy, EMA committee says
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the…
Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again…
